Oncology Failure Atlas

Access Options

Choose how you would like to access Oncology Failure Atlas, expanded evidence releases, and future research workflows.

Oncology Failure Atlas is currently in public-data research early access. Access options support early product validation while giving confidential users a private path.

Public Pilot Partner

Pilot access · individually agreed

Receive pilot access in exchange for being listed as a public pilot partner, only after explicit consent. Pilot access duration and scope are agreed individually after review.

  • Your name and/or organization may appear on the Oncology Failure Atlas pilot partner page.
  • Best for researchers, organizations, or teams comfortable being publicly associated with the pilot.
  • Useful for early collaborators who want to help shape future research releases.
  • Pilot access duration and scope are agreed individually after review.

Public Pilot Partner access is reviewed manually. Duration, scope, and public listing details are agreed before access is granted.

Public Feedback Contributor

1 month free access

Receive 1 month of access in exchange for structured product feedback. Selected feedback may be quoted or reposted publicly only with explicit consent.

  • Best for users willing to help validate the platform.
  • Feedback may cover evidence usefulness, trust, usability, and future research workflows.
  • Public use of feedback requires explicit consent before publication.

Feedback is collected manually for now. Public quotes or reposts require explicit consent.

Private Paid Access

€299/month · billed yearly

Private access for users who want confidential research access without public listing, testimonial, or public feedback requirements.

  • €299/month, billed yearly by invoice.
  • Best for users who want confidentiality.
  • No public attribution required.
  • Suitable for private analysis, diligence, or internal research exploration.

Private access keeps your organization and feedback confidential unless you explicitly agree otherwise.

Access requests are reviewed manually. Email replies, LinkedIn feedback verification, and invoice/payment steps are handled manually for now.

Oncology Failure Atlas · Pharma Innovation Research by Sebastian Azar · oncologyfailureatlas.com · MDIP™ and RecurSignal™ are proprietary frameworks. All rights reserved.